Ricardo Lorenzoni

Ricardo Lorenzoni

Auto-generated profile, based on publicly available information

Ricardo Lorenzoni

Pharmaceutical Sciences Graduate Program, College of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
ACAline Marquez Cardoso
Aline Marquez Cardoso
EOEdilene Gadelha de Oliveira
Edilene Gadelha de Oliveira
KCKarine Coradini
Karine Coradini
FBFranciele Aline Bruinsmann
Franciele Aline Bruinsmann
TATanira Aguirre
Tanira Aguirre
Ruy Carlos Ruver BeckRuy Carlos Ruver Beck
Ruy Carlos Ruver Beck

1 May 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
JAJuan Aparicio-Blanco
Juan Aparicio-Blanco
LSLorena Sanz-Arriazu
Lorena Sanz-Arriazu
RLRicardo Lorenzoni
Ricardo Lorenzoni
María J. Blanco PrietoMaría J. Blanco Prieto
María J. Blanco Prieto

26 June 2023 in Aging Cell
Verified
Journal Article
Open access
DMDaniela Marinho
Daniela Marinho
IFIldete Luísa Ferreira
Ildete Luísa Ferreira
RLRicardo Lorenzoni
Ricardo Lorenzoni
SCSandra Morais Cardoso
Sandra Morais Cardoso
ISIsabel Santana
Isabel Santana
Ana Cristina Cristina RegoAna Cristina Cristina Rego
Ana Cristina Cristina Rego
Several molecular mechanisms have been described in Alzheimer's disease (AD), including repressed gene transcription and mitochondrial and endoplasmic reticulum (ER) dysfunction. In this study, we evaluate the potential efficacy of transcriptional modifications exerted by inhibition or knockdown of class I histone deacetylases (HDACs) in ameliorating ER‐mitochondria cross‐talk in AD models. Data show increased HDAC3 protein levels and decreased acetyl‐H3 in AD human cortex, and increased HDAC2‐3 in MCI peripheral human cells, HT22 mouse hippocampal cells exposed to Aβ1–42 oligomers (AβO) and APP/PS1 mouse hippocampus. Tacedinaline (Tac, a selective class I HDAC inhibitor) counteracted the increase in ER‐Ca2+ retention and mitochondrial Ca2+ accumulation, mitochondrial depolarization and impaired ER‐mitochondria cross‐talk, as observed in 3xTg‐AD mouse hippocampal neurons and AβO‐exposed HT22 cells. We further demonstrated diminished mRNA levels of proteins involved in mitochondrial‐associated ER membranes (MAM) in cells exposed to AβO upon Tac treatment, along with reduction in ER‐mitochondria contacts (MERCS) length. HDAC2 silencing reduced ER‐mitochondria Ca2+ transfer and mitochondrial Ca2+ retention, while knockdown of HDAC3 decreased ER‐Ca2+ accumulation in AβO‐treated cells. APP/PS1 mice treated with Tac (30 mg/kg/day) also showed regulation of mRNA levels of MAM‐related proteins, and reduced Aβ levels. These data demonstrate that Tac normalizes Ca2+ signaling between mitochondria and ER, involving the tethering between the two organelles in AD hippocampal neural cells. Tac‐mediated AD amelioration occurs through the regulation of protein expression at MAM, as observed in AD cells and animal models. Data support transcriptional regulation of ER‐mitochondria communication as a promising target for innovative therapeutics in AD.

1 April 2012 in Journal of Biomedical Nanotechnology
Verified
Journal Article
Closed access
RRRenata P. Raffin
Renata P. Raffin
ALAmanda Lima
Amanda Lima
RLRicardo Lorenzoni
Ricardo Lorenzoni
MAMichelli B. Antonow
Michelli B. Antonow
CTCláudia Turra
Cláudia Turra
SFSolange Binotto Fagan
Solange Binotto Fagan
Lipid nanoparticles are drug delivery systems able to increase bioavailability of poorly soluble drugs. They can be prepared with different lipid materials, especially natural lipids. Shea butter is a natural lipid obtained from the Butyrospermum parkii seed and rich in oleic and stearic acids. Nimesulide is a COX 2 selective anti-inflammatory that is poorly soluble in water. The purpose of this study was to develop and characterize shea butter lipid nanoparticles using a new technique and evaluate the in vivo activity of these nanoparticles. Lipid nanoparticles were prepared by melting shea butter and mixing with an aqueous phase using a high shear mixer. The nanoparticles presented pH of 6.9±0.1, mean particle size of 90 nm and a narrow polydispersity (0.21). Zeta potential was around −20 mV and the encapsulation efficiency was 97.5%. Drug release was evaluated using dialysis bags and presented monoexponential profile with t50% of 4.80 h (free drug t 50% was only 2.86 h). Antinociceptive activity was performed by the acetic acid model. Both nimesulide and nimesulide-loaded nanoparticles presented significant activity compared to the control. The in vivo anti-inflammatory activity was evaluated by paw edema and was statistically different for the nanoparticles containing nimesulide compared to free nimesulide, blank nanoparticles and saline. In conclusion, the use of shea butter as encapsulating lipid was very successful and allowed nanoparticles to be prepared with a very simple technique. The nanoparticles presented significant pharmacological effects that were not seen for free drug administration.

1 August 2020 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
RLRicardo Lorenzoni
Ricardo Lorenzoni
SDSamuel Davies
Samuel Davies
LCLeticia Malgarim Cordenonsi
Leticia Malgarim Cordenonsi
JVJosé Alcides da Silva Viçosa
José Alcides da Silva Viçosa
NMNathana Jamille Mezzomo
Nathana Jamille Mezzomo
VRVirginia Cielo Rech
Virginia Cielo Rech

16 October 2016 in Advances in Materials Science and Engineering
Verified
Journal Article
Open access
PDF file
MAM. B. Antonow
M. B. Antonow
RLR. Lorenzoni
R. Lorenzoni
GBG. M. Barbosa
G. M. Barbosa
AOAline Ferreira Ourique
Aline Ferreira Ourique
PGP. Gomes
P. Gomes
RRR. P. Raffin
R. P. Raffin
Desonide is a topical corticosteroid that has been used for more than 30 years; however, its prolonged use can induce several side effects, affecting dermis and epidermis. The present work consists of development desonide-loaded nanocapsule suspensions (D-NC) using different polymers (Eudragit S100® or Eudragit L100®) and desonide-loaded lipid-core nanocapsules (D-LNC). They were formulated by interfacial deposition using the preformed polymer method and all formulations showed negative zeta potential and adequate nanotechnological characteristics (particle size 161–202 nm, polydispersity index < 0.20). Simple and sensitive methods using high-performance liquid chromatography (HPLC) were developed to quantify desonide in LNC and to study its release kinetics. The method was linear, specific, precise, and exact and therefore can be applied in quantification of D-NC and D-LNC. We evaluatedin vitromethods for drug release (dissolution, Franz diffusion cells, and dialysis sac) and we use mathematical models (monoexponential, biexponential, and Korsmeyer-Peppas) to show release kinetics from this system.